XAIR Beyond Air, Inc.

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

$13.46  -0.94 (-6.53%)
As of 12/03/2021 10:50:19 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  07/15/2019
Outstanding shares:  26,640,039
Average volume:  705,835
Market cap:   $382,550,960
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    08862L103
ISIN:        US08862L1035
Sedol:      
Valuation   (See tab for details)
PE ratio:   -21.62
PB ratio:   8.87
PS ratio:   869.34
Return on equity:   -50.52%
Net income %:   -4,697.68%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy